<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">


Press Releases

Our latest announcements

Biodesix Closes Series D Financing

Biodesix has closed a $20 million series D financing. The new capital will support ongoing commercialization activities for the company's Veristrat.

Biodesix Supports Unique Lung Cancer Research Initiative – CASTLE study enrolls initial subjects

Biodesix announces the enrollment of initial subjects into CASTLE, the inaugural study of the Addario Lung Cancer Medical Institute.

Biodesix Issued Four Additional U.S. Patents for Blood-based Oncology Tests

Biodesix announced that the U.S. Patent & Trademark Office has issued four patents for the protection of the company's products and technology.

Biodesix Receives Certification from NY State

Biodesix has received the clinical laboratory evaluation program certification from the New York State Department of Health’s Wadsworth Center.

Biodesix to Present at 2011 Biotech Showcase

Biodesix's Paul Beresford will present at the 2011 Biotech Showcase conference taking place January 10–12th at the Parc 55 Wyndham in San Francisco, CA

VeriStrat® Test Identifies Lung Cancer Patients Benefiting from Combination Therapy

The intention of the biomarker analysis was to evaluate the ability of VeriStrat, to predict patient outcomes with a combination regimen.

Biodesix Completes Series C Financing and Receives Grant

Biodesix Inc. announced today that the company has raised $7.1 million in new equity financing, led by existing investors.

Biodesix Selected as a Colorado Company to Watch

Biodesix Inc. announced today that they are one of the winners of the 2010 Colorado Companies to Watch award, developing valuable products and services.

Biodesix Announces Issuance of Key Patent for Serum Test that Identifies Lung Cancer Patients Likely to Benefit from Targeted Therapy

Biodesix announced today that the United States Patent and Trademark Office has awarded to the company patent number 7,736,905.

New Data from Phase III Lung Cancer Trial Show VeriStrat® Identifies Patients Likely to Respond to Erlotinib

Phase III trial shows that VeriStrat identified patients likely to respond to erlotinib (Tarceva.)